chris_chi24 said:The mechanism and the magnitude are separate questions.
Agreed, and one caution: a single measurement is not a measurement. Anything that moves day to day needs a trend before it means anything at all.
stefan_berlin said:NASH/MAFLD therapeutic landscape and liver and MASH: GLP-1 agonists are emerging as potential first-line NASH therapy.
This answered a question I did not know how to ask.
chris_chi24 said:The mechanism and the magnitude are separate questions.
Pushing back on chris_chi24 here. This treats a plausible mechanism as a demonstrated one. Plausible is where you start looking, not where you stop.
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsAdding the numbers, since they settle part of this. If you are going to change something, change one thing and give it long enough to express itself. Four weeks is the usual minimum for anything pharmacological on this board, and two weeks of data has told you almost nothing.
Moderator note: a post naming a supplier has been edited. Discuss suppliers in the review sections, not here. No action needed from anybody.